Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01024231 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 127 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | terminated | N/A | 152 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07740642 | A Comparative Usability Study of Two Total Body Skin Imaging Systems | not yet recruiting | N/A | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass) | active not recruiting | Phase 3 | 108 | Aura BiosciencesINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT07574047 | MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. | not yet recruiting | Phase 2 | 108 | Swiss Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04996823 | Axitinib + Ipilimumab in Advanced Melanoma | active not recruiting | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07634380 | Sitagliptin With Pembro in RCC and Melanoma | recruiting | Phase 1 | 64 | Fernando Maciel BarbosaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01587352 | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT06081920 | A Study of IBI363 in Subjects With Advanced Melanoma | recruiting | Phase 2 | 180 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07680452 | Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition(Melafit) | recruiting | N/A | 60 | Charite University, Berlin, GermanyOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05282901 | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)(PLUME) | completed | Phase 2 | 51 | Institut CurieOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05373823 | MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors | recruiting | N/A | 385 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06627595 | Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management(APiTOXMM) | recruiting | — | 160 | University Hospital, MontpellierOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | completed | Phase 1 / Phase 2 | 10 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery | terminated | Phase 2 | 6 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07686835 | Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.(FIGURE-IM) | recruiting | Phase 2 | 70 | Radboud University Medical CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07042243 | The Florida ASCENT Study | recruiting | N/A | 100 | University of FloridaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06666634 | Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy(NANOSCAN) | completed | N/A | 29 | The Netherlands Cancer InstituteOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07230613 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma(NEOREM-NEO-1) | recruiting | Phase 2 | 50 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03225365 | Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma(IMMUNONIVO) | completed | N/A | 5 | Hospices Civils de LyonOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03405155 | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05704647 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06060613 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors(Agni-01) | recruiting | Phase 1 / Phase 2 | 208 | Obsidian Therapeutics, Inc.INDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | suspended | Phase 1 / Phase 2 | 47 | Roswell Park Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06264180 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | recruiting | Phase 3 | 400 | Replimune, Inc.INDUSTRY | 7 | Jul 15, 2026 | clinicaltrials |
| NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | completed | Phase 1 | 90 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | completed | Phase 3 | 266 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02724488 | Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies(SPECIAL) | completed | — | 14 | University Health Network, TorontoOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | recruiting | Phase 1 | 36 | Carlo ContrerasOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | enrolling by invitation | Phase 1 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2026source: clinicaltrials